

PEOPLE

Bristol-Myers Squibb (New York) has announced that **Peter R. Dolan** has succeeded **Charles A. Heimbold, Jr.** as CEO. Mr. Dolan, the seventh chief executive in BMS's history, will retain his title of president and will remain a member of the board of directors. In April, President George W. Bush announced his intention to nominate Mr. Heimbold to become the next US ambassador to Sweden.



Achillion Pharmaceuticals (New Haven, CT) has announced the addition of **Mary Kay Fenton**, formerly senior manager in the Connecticut technology industry group at PricewaterhouseCoopers, to the company as director of corporate finance.

Santarus (San Diego, CA) has appointed **Rodney A. Ferguson** and **Arthur J. Klausner** to its board of directors. Dr. Ferguson is a general partner in the San Francisco office of JPMorgan Partners, the private equity group of JPMorganChase & Co. Mr. Klausner is a general partner at the venture capital firm Domain Associates.

3-Dimensional Pharmaceuticals (Exton, PA) has announced the appointment of **John M. Gill** as executive vice president and chief financial officer. Mr. Gill was formerly at SmithKline Beecham, where he served as vice president and director, operations and finance.

EntreMed (Rockville, MD) has made two executive appointments: **Edward R. Gubish** has been appointed president and chief operating officer. Dr. Gubish has been with EntreMed since 1993 and served most recently as executive vice president for R&D. Additionally, **Neil J. Campbell** has been named vice president of corporate development. Mr. Campbell recently served as senior director of commercial development for Celera Genomics.

Aya Jakobovits has been named senior vice president, technology and corporate development at UroGenesys (Santa Monica, CA). She will also continue to serve as chief scientific officer. Dr. Jakobovits joined UroGenesys in January 1999 as vice president of research and CSO.

Richard D. Katz has been appointed senior vice president, finance and corporate development, and chief financial officer at Icagen (Research Triangle Park, NC). Previously, Mr. Katz was a vice president in the health care group at Goldman Sachs & Co.

Salus Therapeutics (Salt Lake City, UT) has announced that **Richard K. Koehn** has been appointed president and CEO. Mr. Koehn was the founding director of the Center for Advanced Biomedical Biotechnology for the State of New York, a co-founder of the New York Biotechnology Association, and until last year the vice president for research at the University of Utah and president of the University of Utah Research Foundation.

InforMax (Bethesda, MD) has announced the promotion of **Stephen E. Lincoln** to executive vice president, product development and chief scientific officer. Mr. Lincoln joined InforMax in December 2000 as senior vice president of life science informatics.

Roger Longman has been appointed to the board of directors of BioStreet (S. San Francisco, CA). He is currently a managing partner and editor at Windhover Information and is the publisher of *In Vivo: The Business & Medicine Report* and *Start-Up: Windhover's Review of Emerging Medical Ventures*.



Millipore (Bedford, MA) has announced the election of **Francis J. Lunger** as president and chief operating officer. He assumes the role of president from C. William Zadel, who will remain the chairman of the board and CEO. Mr. Lunger joined the company in June 1997 as chief financial officer.

NicOx (Sophia-Antipolis, France) has announced the appointment of **Giancarlo Santus** as vice president, product development, a newly created position. Dr. Santus was most recently director of pharmaceutical technology R&D of Recordati S.p.A.

Signature BioScience (Hayward, CA) has announced the appointment of **David C. Spellmeyer** as chief scientific officer and vice president of drug discovery and **Nancy E. Pecota** to senior director of finance and administration. Before joining Signature, Dr. Spellmeyer was executive director at DuPont Pharmaceuticals Research Laboratories and also vice president of computational sciences at CombiChem. Ms. Pecota was most recently director of finance and accounting at ACLARA BioSciences.

Martin A. Wasserman has been named vice president, discovery research and chief scientific officer of AtheroGenics (Atlanta, GA). He joins the company from Aventis Pharmaceuticals, where he was vice president and senior distinguished scientist in the respiratory and rheumatoid arthritis disease group.